冠状动脉支架的演变:从出生到未来的趋势
Zhuo Huang1,2, Charles Skarbek1,2,3, Yulin Li4,5
1Laboratory for Vascular Translational Science, Inserm U1148, 75018 Paris, France.
Journal of clinical medicine
|January 10, 2026
概括
冠状动脉疾病 (CAD) 治疗已经通过冠状动脉支架显著进步. 本综述详细介绍了支架的演变,从早期血管造形术到现代创新,改善患者的治疗结果并指导未来的设备开发.
科学领域:
- 干预心脏病学 干预心脏病学
- 生物材料科学 生物材料科学
- 医疗设备创新 医疗设备创新
背景情况:
- 冠状动脉疾病 (CAD) 影响全球超过3亿人,是导致死亡的主要原因.
- 使用冠状动脉支架的穿皮冠状动脉干预 (PCI) 是CAD的主要治疗方法.
- 支架技术在过去二十年里不断发展,大大提高了治疗效率.
研究的目的:
- 审查冠状动脉支架的历史发展和演变.
- 分析支架技术的进步如何解决临床挑战.
- 讨论冠状动脉支架设计的未来方向和创新.
主要方法:
- 穿皮冠状动脉干预 (PCI) 和支架开发的历史审查.
- 对技术进步的分析,从气球血管整形到药物释放支架.
- 对生物降解合金和仿生涂料等新兴技术的研究.
主要成果:
- 早期的气球血管整形为支架植入铺平了道路.
- 裸金属和药物排泄支架显著减少了复缩,血栓形成和重复血管化.
- 持续的创新旨在进一步提高支架性能和患者的治疗结果.
结论:
- 冠状动脉支架的历史轨迹对于理解当前的PCI实践至关重要.
- 材料和涂料的持续创新对于解决剩余的挑战至关重要.
- 了解支架进化指导干预心脏病设备创新的未来进展.
相关概念视频
01:27Coronary Artery Disease V: Interprofessional Care
208
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
208
01:26Coronary Artery Disease IV: Preventive Measures
579
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
579